Search PubMed⌕ Search

Biomedical subjects

C Baum

Publications and source records attributed to C Baum.

118 records · Page 7Linked to original sources
PubMedDate not supplied

Trends in use of oral hypoglycemic agents 1964-1986.

Oral hypoglycemic (OH) agents have been available in the United States for the treatment of non-insulin-dependent diabetes mellitus (NIDDM) for almost 30 yr. During this time they have been subject to considerable controversy. In this article, we present pharmaceutical marketing research data that provide a review of several facets of OH use. The number of OH prescriptions dispensed peaked in 1973, decreased through 1980, and has been increasing since that year. In 1986, OH agents accounted for 21.5 million prescriptions: 1% of all prescriptions dispensed that year. Chlorpropamide is currently the most frequently ingested OH agent; it is used by 33% of the market. The two OH agents introduced in 1984, glyburide and glipizide, had acquired 41% of the OH market by the end of 1986. The rate of OH use per 1000 diabetes mellitus visits increases with patient's age. Patients aged 60 yr and older received OH prescriptions at a rate of 478 per 1000 diabetes mellitus visits in 1986. Data estimating both the number of patients diagnosed with diabetes and the number of diabetic patients taking OH agents indicate that the percentage receiving OH treatment has increased over the past 5 yr, with approximately 35% of all diabetic patients taking OH agents in 1986.

Diabetes Mellitus, Type 2↗
PubMedDate not supplied

Removal of amalgam, glass-ionomer cement and compomer restorations: changes in cavity dimensions and duration of the procedure.

This study investigated changes in the dimensions of Class II cavities following the removal of amalgam, glass ionomer and compomer restorations. In 30 extracted caries-free human molars, preparation for 60 mesio-occlusal and occluso-distal cavities (two cavities per tooth) occurred. With a CEREC 3 laser triangulation sensor and software-based construction analysis, the dimensions of the cavities at seven defined sites were measured. The cavities were randomized into four groups. Group 1 was restored with Ketac-Fil glass-ionomer cement, Group 2 with amalgam and Group 3 with Compoglass F compomer. In Group 4, Compoglass F was used in combination with photochromic Tetric Flow Chroma as a cavity liner. The completed restorations were then removed using 2x magnification and the cavities were once again controlled using the laser system. The duration of the removal procedure was also recorded. Changes in cavity dimensions (depth, height and width) following removal of the restorations were significantly smaller in Groups 1 and 2. Groups 3 and 4 were characterized by a significant overextension of the cavities compared to Groups 1 and 2 in all three dimensions. Group 4, with Tetric Flow Chroma as a cavity liner, showed better results than Group 3, but this improvement was not statistically significant. The duration of the removal procedure was significantly shorter in Group 2 than in the other groups.

Compomers↗
PubMedDate not supplied

The impact of the addition of naloxone on the use and abuse of pentazocine.

An epidemic of abuse with "T's and blues" began in the late 1970's in which pentazocine-Talwin tablets ("T")--and the antihistamine tripelennamine (known as blues) were crushed, dissolved together, filtered, and injected intravenously. The resulting high was reported to be similar to that of heroin. In 1981, the manufacturer and the Food and Drug Administration met to discuss a possible solution. As a result, 0.5 mg of naloxone hydrochloride, a narcotic antagonist that is pharmacologically inactive at that dose orally but active if administered parenterally, was added to the tablet formulation. The reformulated product, Talwin Nx, was approved for marketing in late 1982 and introduced in the second quarter of 1983. Distribution of Talwin tablets in the United States was discontinued. The Drug Abuse Warning Network (DAWN) of the National Institute of Drug Abuse and IMS America's National Prescription Audit were used to review the use and abuse patterns of pentazocine before and after the naloxone intervention. The number of prescriptions dispensed quarterly for pentazocine products remained fairly stable from 1981 through the first quarter of 1983 and increased after the introduction of Talwin Nx. In contrast, DAWN emergency room and medical examiner mentions decreased after the product reformulation. The rates of both emergency room and medical examiner mentions per million prescriptions were substantially lower in the 2 years following the introduction of Talwin Nx (decreases of 70 percent by emergency rooms and 71 percent by medical examiners), indicating that the product reformulation successfully reduced pentazocine abuse.

Coroners and Medical Examiners↗